Osteoarthrosis: possibilities of complex use of the medication Zeel T within the framework of bioregulatory approach

Abstract

Background: In the article it is considered the essence and possibilities of the bioregulatory approach in the therapy of osteoarthrosis/osteoarthritis (OA) that is realized with the help of the use of complex bioregulatory medications (CBM) of the German company Biologische Heilmittel Heel GmbH. It is described in detail the composition and characteristics of the CBM Zeel T – the chondroprotective compound with a bioregulatory action. Zeel T is registered in the Republic of Moldova as a solution for injections, sublingual tablets and cream. Zeel T contributes to the restoration of the disturbed metabolic and reparative processes in the articular cartilage. There are considered important distinguishable moments of the mechanism of Zeel T action from the traditional chondroprotective compounds and its advantages. It should be noted that Zeel T has more than 40 years research history and it is widely used in more than 30 countries. Every year almost one million patients worldwide are treated with Zeel T. In the article it is presented the overview of clinical studies on the use of Zeel T at OA that demonstrate that Zeel T has comparable clinical efficacy with various traditional medicinal products (MP). Conclusions: It has also a good tolerability, does not cause characteristic for NSAIDs and corticosteroids (CS) side effects, and therefore can be used for a long time. The medicine is well combined with other medicinal products that increases the effectiveness and reduces the duration of the treatment course of OA.